Skip to main content
SpringerLink
Log in

Probiotics and Inflammatory Bowel Disease

  • Therapy Review
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Inflammatory bowel disease (IBD) is characterised by a chronic dysregulation of the inflammatory response in the gastrointestinal tract. While the pathogenesis is unclear, studies have demonstrated that the gastrointestinal tracts of patients with IBD are populated with increased levels of adherent and pathogenic bacteria. This evidence, combined with growing data accumulated from genetic studies as well as animal models of IBD, indicates that an aberrant response to altered enteric flora plays a significant role in the disease process.

Current therapies for IBD have been directed towards the development of anti-inflammatory agents and immunomodulators to attenuate the inflammatory response in the gastrointestinal tract. Antibiotics are also partially effective in the treatment of IBD, presumably by altering the bowel flora. However, it is clear from clinical trials that immunomodulators and antibiotics are not effective in a large proportion of patients with IBD and other therapeutic alternatives need to be pursued.

Probiotics are microbial supplements capable of recolonising the bowel with non-pathogenic strains of bacteria or yeast. Probiotics have long been shown to be beneficial in both infectious and non-infectious digestive disorders. Growing evidence indicates that probiotics may be effective in the treatment of specific clinical IBD conditions. This article addresses the current evidence for the role of enteric flora in the pathogenesis of IBD and the clinical evidence supporting the use of probiotics in specific clinical IBD conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Donowitz M. The burden of gastrointestinal diseases. Bethesda: American Gas-troenterological Association, 2001: 30–40

    Google Scholar 

  2. Farrell RJ, Banerjee S, Peppercorn MA. Recent advances in inflammatory bowel disease. Crit Rev Clin Lab Sci 2001; 38: 33–108

    Article  PubMed  CAS  Google Scholar 

  3. Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 2001; 120: 1347–55

    Article  PubMed  CAS  Google Scholar 

  4. Lilly DM, Stillwell RH. Probiotics: growth promoting factors produced by microorganisms. Science 1965; 47: 747–8

    Article  Google Scholar 

  5. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents: a neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996; 275: 870–6

    Article  PubMed  CAS  Google Scholar 

  6. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora [letter]. Lancet 1989; I: 164

    Article  Google Scholar 

  7. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001; 120: 622–35

    Article  PubMed  CAS  Google Scholar 

  8. Slezak M. Emerging treatments for IBD. Gastroenterology and Endoscopy News Oct 2001; 53(10): 1–8

    Google Scholar 

  9. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 41–62

    Article  PubMed  Google Scholar 

  10. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448–55

    Article  PubMed  CAS  Google Scholar 

  11. Sartor RB. Enteric microflora in IBD: pathogens or commensals? Inflamm Bowel Dis 1997; 3: 230–5

    Article  Google Scholar 

  12. Rutgeerts P, Goboes K, Peeter M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1991; 338: 771–4

    Article  PubMed  CAS  Google Scholar 

  13. Sandborn WJ, Landers CJ, Tremaine WJ, et al. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995; 90: 740–7

    PubMed  CAS  Google Scholar 

  14. D’Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262–7

    Article  PubMed  Google Scholar 

  15. Harper PH, Lee EC, Kettlewell MG, et al. Role of the faecal stream in the maintenance of Crohn’s colitis. Gut 1985; 26: 279–84

    Article  PubMed  CAS  Google Scholar 

  16. Sartor RB. Microbial factors in the pathogenesis of Crohn’s disease, ulcerative colitis, and experimental intestinal inflammation. In: Kirsner JB, editor. Inflammatory bowel disease. Philadelphia: WB Saunders, 2000: 153–178

    Google Scholar 

  17. Shanahan F. Probiotics in inflamatory bowel disease. Gut 2001; 48: 609

    Article  PubMed  CAS  Google Scholar 

  18. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44–54

    Article  PubMed  Google Scholar 

  19. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 1992; 33: 646–50

    Article  PubMed  CAS  Google Scholar 

  20. Giaffer MH, Holdsworth CD, Duerden BI. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 1991; 35: 238–43

    Article  PubMed  CAS  Google Scholar 

  21. Favier C, Neut C, Mizon C, et al. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn’s disease. Dig Dis Sci 1997; 42: 817–22

    Article  PubMed  CAS  Google Scholar 

  22. Walmsley RS, Anthony A, Sim R, et al. Absence of Escherichia coli, Listeria monocytogenes, and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues. J Clin Pathol 1998; 51: 657–61

    Article  PubMed  CAS  Google Scholar 

  23. Kennedy RJ, Kirk SJ, Gardiner KR. Promotion of a favorable gut flora in inflammatory bowel disease. JPEN J Parenter Enterai Nutr 2000; 24: 189–95

    Article  CAS  Google Scholar 

  24. Burke DA, Axon AT. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ 1988; 297: 102–4

    Article  PubMed  CAS  Google Scholar 

  25. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbio Rev 1993; 12: 221–38

    Article  CAS  Google Scholar 

  26. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/ human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945–53

    Article  PubMed  CAS  Google Scholar 

  27. Contractor NV, Bassiri H, Reya T, et al. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol 1998; 160: 385–94

    PubMed  CAS  Google Scholar 

  28. Dianda L, Hanby AM, Wright NA, et al. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997; 150: 91–7

    PubMed  CAS  Google Scholar 

  29. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 5224–31

    PubMed  CAS  Google Scholar 

  30. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116: 1107–14

    Article  PubMed  CAS  Google Scholar 

  31. Schultz M, Veitkamp C, Dieleman LA, et al. Continuous feeding of Lactobacillus plantarum attenuates established colitis in interleukin-10 deficient mice [abstract]. Gastroenterology 1998; 114: A4426

    Article  Google Scholar 

  32. Kennedy RJ, Hoper M, Weir H, et al. Probiotic therapy stabilizes the gut mucosal barrier in the interleukin 10 knockout model of colitis [abstract]. Br J Surg 2000; 87: 669

    Google Scholar 

  33. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001; 357: 1925–8

    Article  PubMed  CAS  Google Scholar 

  34. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411: 599–603

    Article  PubMed  CAS  Google Scholar 

  35. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411: 603–6

    Article  PubMed  CAS  Google Scholar 

  36. Malin M, Suomalainen H, Saxelin M, et al. Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996; 40: 137–45

    Article  PubMed  CAS  Google Scholar 

  37. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 1999; 116: 1246–9

    Article  PubMed  CAS  Google Scholar 

  38. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000; 6: 107–15

    Article  PubMed  CAS  Google Scholar 

  39. Bengmark S. Ecological control of the gastrointestinal tract: the role of probiotic flora. Gut 1998; 42: 2–7

    Article  PubMed  CAS  Google Scholar 

  40. Gordon JI, Hooper LV, McNevin MS, et al. Epithelial cell growth and differentiation: III. promoting diversity in the intestine: conversations between the microflora, epithelium, and diffuse GALT. Am J Physiol 1997; 273: G565–70

    PubMed  CAS  Google Scholar 

  41. Mourelle M, Salas A, Guarner F, et al. Stimulation of transforming growth factor betal by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 1998; 114:519–26

    Article  PubMed  CAS  Google Scholar 

  42. Hamilton-Miller JMT. A review of clinical trials of probiotics in the management of inflammatory bowel disease. Infect Dis Res 2001; 3: 83–87

    Google Scholar 

  43. Gupta P, Andrew H, Kirschner BS, et al. Is lactobacillus GG helpful in children with Crohn’s disease?: results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31: 453–7

    Article  PubMed  CAS  Google Scholar 

  44. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000; 45: 1462–4

    Article  PubMed  CAS  Google Scholar 

  45. Malchow HA. Crohn’s disease and Escherichia coli: a new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 1997; 25: 653–8

    Article  PubMed  CAS  Google Scholar 

  46. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635–9

    Article  PubMed  CAS  Google Scholar 

  47. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853–8

    Article  PubMed  CAS  Google Scholar 

  48. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103–8

    Article  PubMed  CAS  Google Scholar 

  49. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305–9

    Article  PubMed  CAS  Google Scholar 

  50. Nissle A. Ubersicht uber die bedeutung bakeriologischer stuhluntersuchgen beinichtinfektiosen darmerkrankungen. Arch Hyg Bakteriol 1930; 103: 124–31

    Google Scholar 

  51. Nissle A. Das problem der dysbakterie des dickdarms und ihrer behandlung. Klin Wochenschr 1932; 13: 1456–9

    Article  Google Scholar 

  52. McCann ML, Abrams RS, Nelson Jr RP. Recolonization therapy with nonadhesive Escherichia coli for treatment of inflammatory bowel disease. Ann N Y Acad Sci 1994; 730: 243–5

    Article  PubMed  CAS  Google Scholar 

  53. Blum G, Marre R, Hacker J. Properties of Escherichia coli strains of serotype O6. Infection 1995; 23: 234–6

    Article  PubMed  CAS  Google Scholar 

  54. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study [abstract]. Pediatrics 1999; 104: e64

    Article  PubMed  CAS  Google Scholar 

  55. Biller JA, Katz AJ, Flores AF, et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995; 21: 224–6

    Article  PubMed  CAS  Google Scholar 

  56. Hilton E, Kolakowski P, Smith M, et al. Efficacy of Lactobacillus GG as a diarheal preventative in travelers diarrhea. J Travel Med 1996; 4: 41–3

    Article  Google Scholar 

  57. Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of travellers’ diarrhoea by Lactobacillus GG. Ann Med 1990; 22: 53–6

    Article  PubMed  CAS  Google Scholar 

  58. Alander M, Satokari R, Korpela R, et al. Persistence of colonization of human colonie mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 1999; 65: 351–4

    PubMed  CAS  Google Scholar 

  59. Bernet MF, Brassart D, Neeser JR, et al. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35: 483–9

    Article  PubMed  CAS  Google Scholar 

  60. Silva M, Jacobus NV, Deneke C, et al. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987; 31: 1231–3

    Article  PubMed  CAS  Google Scholar 

  61. Dias RS, Bambirra EA, Silva ME, et al. Protective effect of Saccharomyces boulardii against the cholera toxin in rats. Braz J Med Biol Res 1995; 28: 323–5

    PubMed  CAS  Google Scholar 

  62. Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonie mucosa. Infect Immun 1999; 67: 302–7

    PubMed  CAS  Google Scholar 

  63. Bleichner G, Blehaut H, Mentec H, et al. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients: A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med 1997; 23: 517–23

    Article  PubMed  CAS  Google Scholar 

  64. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebocontrolled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913–8

    Article  PubMed  CAS  Google Scholar 

  65. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea: a pilot study. Z Gastroenterol 1993; 31: 129–34

    PubMed  CAS  Google Scholar 

  66. Hamilton-Miller JMT, Gibson GR. Efficacy studies of probiotics: a call for guidelines. Br J Nutr 1999; 82: 73–5

    PubMed  CAS  Google Scholar 

  67. Kimmey MB, Elmer GW, Surawicz CM, et al. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci 1990; 35: 897–901

    Article  PubMed  CAS  Google Scholar 

  68. Lee YK, Salminen S. The coming of age of probiotics. Trends Food Sci Tech 1995; 6: 241–5

    Article  Google Scholar 

  69. Katz JA, Pirovano F, Matteuzzi D, et al. Commercially available probiotic preparations: are you getting what you pay for? [abstract]. Gastroenterology 2002; 122: A459

    Google Scholar 

  70. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352–5

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Dana 501, 330 Brookline Ave, Boston, Massachusetts, 02215, USA

    John H Kwon &  Richard J Farrell

Authors
  1. John H Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard J Farrell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard J Farrell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kwon, J.H., Farrell, R.J. Probiotics and Inflammatory Bowel Disease. BioDrugs 17, 179–186 (2003). https://doi.org/10.2165/00063030-200317030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200317030-00004

Keywords

Search

Navigation